Remove 2021 Remove Trials Remove Virus
article thumbnail

Current insights and molecular docking studies of HIV?1 reverse transcriptase inhibitors

Chemical Biology and Drug Design

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine.

article thumbnail

Moderna to Build mRNA Vaccine Portfolio Following COVID-19 Success | 2021-01-11

The Pharma Data

Using the same technology, it is now developing a seasonal flu vaccine program to cover four seasonal viruses recommended by the World Health Organization, with a phase 1 clinical trial scheduled to begin this year. Of those two dozen programs, 13 are now in clinical trials. It has already received $2.8 It has already received $2.8

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Day Zero Antivirals for Future Pandemics

Codon

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 99
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69
article thumbnail

Moderna says its COVID-19 vaccine shows promise in elderly patients

The Pharma Data

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . These antibodies were higher than those seen in people who had recovered from the virus. There is hope that Moderna’s vaccine could be available by early 2021. .

Vaccine 90
article thumbnail

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

The Pharma Data

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. The overall safety profile of nirsevimab in the trial remains consistent with previously reported results.

Virus 40
article thumbnail

Existing drug is shown to inhibit virus that causes COVID-19

The Pharma Data

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S. .”

Virus 52